Alsevalimab is currently evaluation as a experimental medicinal antibody targeting human B7-H4. This immunotherapy has shown preclinical efficacy in multiple cancer forms by blocking B7H4's function in cancerous growth https://fpa150193415.pointblog.net/alsevalimab-a-emerging-anti-b7h4-antibody-in-investigation-94802410